Subt. Form PTO-1449				Docket Number	Application Number
INFORMATION DISCLOSURE IN AN APPLICATION				HYZ-069CN (47508.530)	09/837,806
(Use several sheets if necessary)				Applicant: Agrawal	
Sheet	2	OF	3	Filing Date: April 18, 2001	Group Art Unit: 1635

	A14	Beaucage (1993) "Oligodeoxyribonucleotides Synthesis" in Methods in Molecular Biology, Vol. 20: Protocols for Oligonucleotides and Analogs, (Agrawal, ed.) Humana Press, Totowa, NJ, pp.33-61
	A15	Brown (1993) "A Brief History of Oligonucleotide Synthesis" in Methods in Molecular Biology, Vol. 20: Protocols for Oligonucleotides and Analogs," pp. 1-17
	A16	Craig et al. (1997) "Patent strategies in the antisense oligonucleotide based therapeutic approach" *Exp. Opin. Ther. Patents* 7(10):1175-1182
	A17	*Database CAS Registry* (2003), (Date of entry: 1997), Registry number 193635-63-1
	A18	Froehler (1993) "Oligodeoxynucleotide Synthesis," Methods in Molecular Biology, Vol. 20: Protocols for Oligonucleotides and Analogs (Agrawal, ed.) Humana Press, Towtowa, NJ, pp. 63-80
	A19	Galderisi et al. (1999) "Antisense Oligonucleotides as Therapeutic Agents" *J. Cell. Physiol.* 181:251-257
	A20	Gewirtz et al. (1996) "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver On Its Promise," *Proc. Natl. Acad. Sci. USA* 93:3161-3163
	A21	Goodchild et al. (1988) "Inhibition of Human Immunodeficiency Virus Replication by Antisense Oligodeoxynucleotides," *Proc. Natl. Acad. Sci. USA* 85:5507-5511
	A22	Harrison et al. (1991) "Determination of the Secondary Structure of the Packaging Signal of HIV-1" in RNA Tumor Viruses (Coffin et al., eds.) Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p. 235
	A23	Iyer et al. (1995) "A Novel Nucleoside Phosphoramidite Synthon Derived From *1R*, 2*S*-Ephedrine," *Tetrahedron: Asymmetry* 6(5):1051-1054
	A24	Krieg et al. (1995) "CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation," *Nature* 374:546-549
	A25	Lisziewicz et al. (1992) "Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication by Antisense Oligonucleotides: An *In Vitro* Model for Treatment", *Proc. Natl. Acad. Sci. USA* 89:11209-11213
	A26	Lisziewicz et al. (1993) "Long-Term Treatment of Human Immunodeficiency Virus-Infected Cells with Antisense Oligonucleotide Phosphorothioates", *Proc. Natl. Acad. Sci. USA* 90:3860-3864
	A27	Lisziewicz et al. (1994) "Antisense Oligodeoxynucleotide Phosphorothioate Complementary to Gag mRNA Blocks Replication of Human Immunodeficiency Virus Type 1 in Human Peripheral Blood Cells", *Proc. Natl. Acad. Sci. USA* 91:7942-7946
	A28	Matsukura et al. (1988) "Synthesis of Phosphorothioate Analogues of Oligodeoxyribonucleotides and Their Antiviral Activity Against Human Immunodeficiency Virus (HIV)," *Gene* 72:343-347
	A29	Matsukura et al. (1989) "Regulation of Viral Expression of Human Immunodeficiency Virus *In Vitro* by an Antisense Phosphorothioate Oligodeoxynucleotide Against *rev(art/trs)* in Chronically Infected Cells," *Proc. Natl. Acad. Sci. USA* 86:4244-4248
	A30	Matsukura et al. (1991) "A New Concept in AIDS Treatment: An Antisense Approach and Its Current Status Towards Clinical Application," In Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS (Wickstrom, ed.), Wiley-Liss, Inc., pp. 159-178
	A31	Metelev et al. (1998) "HPLC of Oligodeoxyribonucleoside Phosphorothioates", Abstract No. 151268f, *Chemical Abstracts*, 128(13):272
	A32	Metelev, et al. (1997) "HPLC of Oligodeoxyribonucleoside Phosphorothioates" *Russian Journal of Bioorganic Chemistry*, 23(9):673-677, Translated from Bioorganicheskaya Khimiya 23(9):742-746
	A33	Milligan, et al. (1993) "Current Concepts in Antisense Drug Design", *Journal of Medicinal Chemistry*, 36(14):1923-1937
	A34	Milner et al. (1997) "Selecting Effective Antisense Reagents on Combinatorial Oligonucleotide Arrays," *Nature Biotech.* 15:537-541
	A35	Rojanasakul (1996) "Antisense Oligonucleotide Therapeutics: Drug Delivery and Targeting," *Adv. Drug Del. Rev.* Vol. 18:115-131
	A36	Sarin et al. (1988) "Inhibition of Acquired Immunodeficiency Syndrome Virus by Oligodeoxynucleoside Methylphosphonates," *Proc. Natl. Acad. Sci. USA* 85:7448-7451
	A37	Sonveaux (1994) "Protecting Groups in Oligonucleotide Synthesis," Methods in Molecular Biology, Vol. 26: Protocols for Oligonucleotide Conjugates (Agrawal, ed.), pp. 1-71
	A38	Tang et al. (1993) "Self-Stabilized Antisense Oligodeoxynucleotide Phosphorothioates: Properties and Anti-HIV Activity," *Nucleic Acids Res.* 21(11):2729-2735
	A39	Uhlmann et al. (1990) "Antisense Oligonucleotides: A New Therapeutic Principle," *Chem. Rev.* 90(4):543-584

EXAMINER	DATE CONSIDERED
	12/13/03

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subt. Form PTO-1449				Docket Number	Application Number
INFORMATION DISCLOSURE IN AN APPLICATION				HYZ-069CN (47508.530)	09/837,806
(Use several sheets if necessary)				Applicant: Agrawal	
Sheet	1	OF	3	Filing Date: April 18, 2001	Group Art Unit: 1635

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,309,404	01/05/82	DeNeale et al.			
	4,309,406	01/05/82	Guley et al.			
	4,556,552	12/03/85	Porter et al.			
	4,704,295	11/03/87	Porter et al.			
	5,627,277	05/06/97	Cohen et al.			

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	WO 94/08004	04/14/94	PCT				
	WO 95/18813	07/13/95	PCT				
	WO96/12497	05/02/96	PCT				
	WO 97/06662	02/27/97	PCT				
	WO 98/40058	9/17/1998	PCT				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

	A1	Agrawal et al. (1987) "Oligodeoxynucleoside Methylphosphonates: Synthesis and Enzymic Degradation," *Tetrahedron. Lett.* 28(31):3539-3542
	A2	Agrawal et al. (1988) "Oligodeoxynucleoside Phosphoramidates and Phosphorothioates as Inhibitors of Human Immunodeficiency Virus, *Proc. Natl. Acad. Sci. USA* 85:7079-7083
	A3	Agrawal et al. (1989) "Inhibition of Human Immunodeficiency Virus in Early Infected and Chronically Infected Cells by Antisense Oligodeoxynucleotides and Their Phosphorothioate Analogues," *Proc. Natl. Acad. Sci. USA* 86:7790-7794
	A4	Agrawal (1991) "Antisense Oligonucleotides: A Possible Approach for Chemotherapy of Aids", In Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS, (Wickstrom, ed.) Wiley-Liss, Inc., pp. 143-158
	A5	Agrawal (1992) "Antisense Oligonucleotides as Antiviral Agents," *Trends in Biotechnology* 10:152-158
	A6	Agrawal et al. (1992) "Cellular Uptake and Anti-HIV Activity of Oligonucleotides and Their Analogs," Gene Regulation: Biology of Antisense RNA and DNA (Erickson and Izant, eds.) Raven Press Ltd., New York, pp. 273-283
	A7	Agrawal, et al. (1992) "GEM*91 – An Antisense Oligonucleotide Phosphorothioate as a Therapeutic Agent for AIDS", *Antisense Res. Dev.* 2:261-266
	A8	Agrawal et al. (1994) "Potential for HIV-1 Treatment with Antisense Oligonucleotides", *J. Biotech. in Healthcare*, 1(2):167-182.
	A9	Agrawal, et al. (1995) "Pharmacokinetics of Antisense Oligonucleotides", *Clin. Pharmacokinet.* 28(1):7-16
	A10	Agrawal et al. (1995) "Absorption, Tissue Distribution and *In Vivo* Stability in Rats of a Hybrid Antisense Oligonucleotide Following Oral Administration," *Biochem. Pharmacol.* 50(4):571-576
	A11	Agrawal (1996) "Preface" In Methods in Molecular Medicine: Antisense Therapeutics (Agrawal,ed.) pp. v-vii
	A12	Agrawal, et al. (1998) "Pharmacokinetics and Bioavailability of Antisense Oligonucleotides Following Oral and Colorectal Administrations in Experimental Animals", In Handbook of Experimental Pharmacology, Vol. 131: Antisense Research and Application, Springer-Verlag, pp. 525-543
	A13	Agrawal (1999) "Importance of Nucleotide Sequence and Chemical Modifications of Antisense Oligonucleotides," *Biochemica et Biophysica Acta* 1489:53-68

EXAMINER	DATE CONSIDERED
	12/13/03

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subt. Form PTO-1449				Docket Number	Application Number
INFORMATION DISCLOSURE IN AN APPLICATION				HYZ-069CN (47508.530)	09/837,806
(Use several sheets if necessary)				Applicant: Agrawal	
Sheet	3	OF	3	Filing Date: April 18, 2001	Group Art Unit: 1635

	A40	Vickers et al. (1991) "Inhibition of HIV-LTR Gene Expression by Oligonucleotides Targeted to the TAR Element," *Nucleic Acids Res.* 19(12):3359-3368
	A41	Wickstrom (1986) "Oligodeoxynucleotide Stability in Subcellular Extracts and Culture Media," *J. Biochem. Biophys. Meth.* 13:97-102
	A42	Zamecnik et al. (1986) "Inhibition of Replication and Expression of Human T-cell Lymphotropic Virus Type III in Cultured Cells by Exogenous Synthetic Oligonucleotides Complementary to Viral RNA," *Proc. Natl. Acad. Sci. USA* 83:4143-4146
	A43	Zamecnik (1996) "History of Antisense Oligonucleotides" in Methods in Molecular Medicine: Antisense Therapeutics (Agrawal,ed.) Humana Press, Totowa, NJ, pp. 1-11
	A44	Zhang et al. (1995) "*In Vivo* Stability, Disposition and Metabolism of a "Hybrid" Oligonucleotide Phosphorothioate in Rats," *Biochem. Pharmacol.* 50(4): 545-556
	A45	Zhang et al. (1995) Pharmacokinetics of an Anti-Human Immunodeficiency Virus Antisense Oligodeoxynucleotide Phosphorothioate (GEM 91) in HIV-Infected Subjects", *Clin. Pharmacol. Ther.* 58(1):44-53.
	A46	Zhang et al. (1996) "Pharmacokinetics and Tissue Disposition of a Chimeric Oligodeoxynucleoside Phosphorothioate in Rats After Intravenous Administration," *Journal of Pharmacology and Experimental Therapeutics* 278(2):971-979
	A47	Zhao et al. (1996) "Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation," *Biochem. Pharmacol.* 51(2):173-182
	A48	Zhao, et al. (2000) "Immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside", *Bioorganic & Medicinal Chemistry Letters*, 10:1051-1054

EXAMINER	DATE CONSIDERED
	12/13/03

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.